Free shipping on all orders over $ 500

JD-5037

Cat. No. M9691
JD-5037 Structure
Synonym:

JD5037; CRB-4001

Size Price Availability Quantity
5mg USD 100  USD100 In stock
10mg USD 170  USD170 In stock
25mg USD 390  USD390 In stock
50mg USD 540  USD540 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

JD-5037 is a cannabinoid-1 receptor blocker (CB1R antagonist) with IC50 of 1.5 nM. JD-5037 is very selective for the CB1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB2 receptors. In vivo, JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice.

Chemical Information
Molecular Weight 572.51
Formula C27H27Cl2N5O3S
CAS Number 1392116-14-1
Solubility (25°C) DMSO ≥ 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Ibrahim Knani, et al. Mol Metab. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome

[2] Bani Mukhopadhyay, et al. Hepatology. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms

[3] Robert J Chorvat, et al. Bioorg Med Chem Lett. Peripherally restricted CB1 receptor blockers

[4] Robert J Chorvat, et al. Bioorg Med Chem Lett. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities

Related Cannabinoid Products
Vicasinabin

Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2).

INV-347

INV-347 is a CB1R inverse agonist that can be used in studies related to obesity.

RVD-Hpα TFA

RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist.

Hemopressin(human, mouse) TFA

Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates.

Hemopressin(rat) TFA

Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates.

  Catalog
Abmole Inhibitor Catalog




Keywords: JD-5037, JD5037; CRB-4001 supplier, Cannabinoid, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.